Gastrointestinal Stromal Tumor (GIST)

Adult trials (Ages 18 and older)

- Interventional trials
  - All Mutation Types (KIT, PDGFRA D842V, Wild)
    - 2nd Line Only
      - IRB #19262
        A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
    - 3rd or 4th Line
      - IRB #22722
        Phase 1, Multi-center, Open-label Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced GIST
      - IRB #22777
        A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors.
      - IRB #17155
        A Multicenter Phase 1, Open-label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

- PDGFRA D842V Only
  - 2nd or 3rd Line
    - IRB #21884
      An Open-label, Phase 2 Efficacy Study of Temozolomide in Advanced SDH-Mutant/Deficient GIST

- SDH-Mutant/deficient GIST

Adult and Pediatrics

- Interventional trials

CROSS-DISEASE TRIALS:

- IRB# 19992 EAY131 (MATCH)
- IRB# 18084 S1609 (DART)

http://www.ohsu.edu/research/rdas/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold